<DOC>
	<DOCNO>NCT01192152</DOCNO>
	<brief_summary>The purpose study demonstrate bioequivalence ( BE ) 5 mg saxagliptin/1000 mg metformin extend release ( XR ) fixed-dose combination ( FDC ) tablet ( manufactured Mt Vernon , Indiana ) relative coadministered 5 mg Onglyza tablet ( saxagliptin , manufacture Mt Vernon , Indiana ) two 500 mg Glucophage XR tablet ( metformin XR , manufacture Evansville , Indiana ) feed state healthy subject .</brief_summary>
	<brief_title>Bioequivalence Study Fixed Dose Combination 5 mg Saxagliptin/1000 mg Metformin XR ( Manufactured Mt Vernon , IN ) Relative 5 mg Onglyza 2 × 500 mg Glucophage XR</brief_title>
	<detailed_description>This study design evaluate FDC tablet 5 mg saxagliptin/1000 mg metformin extend release ( manufactured Mt Vernon , Indiana ) bioequivalent coadministered 5 mg saxagliptin tablet plus 2 x 500 mg Glucophage XR tablet ( manufacture Evansville , Indiana )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male female subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m² , inclusive Ages 18 55 , inclusive Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination beyond consistent target population Major surgical procedure within 4 week prior randomization Positive serology test HIV , HBV HCV Clinically significant history presence follow condition : heart , liver , kidney disease , neurologic psychiatric disease History gastrointestinal disease within past 3 month Any clinically significant medical condition could potentially affect participation study and/or personal wellbeing , judge investigator Donated blood blood product blood bank , blood transfusion participate clinical study ( except screen visit ) require withdrawal blood within 4 week prior randomization Unable tolerate oral and/or intravenous ( IV ) medication Unable tolerate puncturing vein draw blood Known allergy hypersensitivity component study medication History significant drug allergy ( anaphylaxis hepatotoxicity ) Used prescription drug counter product control acid ( example , Prevacid , Mylanta Rolaids ) within 4 week prior randomization Used drug include counter medication herbal preparation within 1 week prior randomization Taken investigational drug placebo ( inactive drug ) within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>